Clinical Trials

116 enrolled

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT07452601 2026-03-05

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Pancreatic cancer, adult

NCT07432594 2026-02-25

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

82 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07361991 2026-01-23

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

50 enrolled

Advan'ce'd

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

720 enrolled

Squamous NSCLC

NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

Lung Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT07272109 2025-12-15

PTCA199-16

210 enrolled

Pancreatic Neoplasms

NCT07258147 2025-12-02

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

30 enrolled

Lung Neoplasms

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

164 enrolled

Breast Neoplasms

NCT07200947 2025-10-01

QL1706

Carcinoma, Non-Small-Cell Lung

NCT07088731 2025-09-22

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

180 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07018063 2025-06-12

YOUNG-NEOS

35 enrolled

Phase NA Not yet recruiting

Neoplasms, Stomach Neoplasms

NCT06975644 2025-05-22

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

55 enrolled

Triple Negative Breast Neoplasms

NCT06861894 2025-05-15

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

164 enrolled

Esophageal Squamous Cell Carcinoma

NCT05982522 2025-04-30

IN10018 Combination Therapy in Previously-treated Solid Tumors

72 enrolled

Other solid neoplasm

Solid Tumor

NCT06894459 2025-04-30

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

180 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

474 enrolled

Esophageal Squamous Cell Carcinoma

NCT06849492 2025-02-27

SHIFT-001

120 enrolled

Advanced Triple Negative Breast Cancer

NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

160 enrolled

Locally Advanced Non-Small Cell Lung Cancer

NCT06793761 2025-01-27

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

260 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT06728618 2024-12-11

OSCC

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

104 enrolled

Pancreatic Neoplasms

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT06604351 2024-09-19

Example

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06513455 2024-07-22

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

132 enrolled

Pancreatic Neoplasms

NCT06454435 2024-06-12

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

158 enrolled

Phase 4 Not yet recruiting

Stomach Neoplasms

NCT06388135 2024-04-29

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT06361030 2024-04-11

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

40 enrolled

Anophthalmia with pulmonary hypoplasia, Pancreatic Neoplasms

NCT06178211 2023-12-20

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

36 enrolled

Esophageal Squamous Cell Carcinoma

NCT06140576 2023-11-20

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

58 enrolled

Breast Neoplasms

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer

NCT05896787 2023-06-09

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

124 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05816694 2023-04-18

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

50 enrolled

Thymoma

NCT04825938 2021-04-28

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Head & NeckOther neoplasm

15 enrolled

Salivary Gland Malignant Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

522 enrolled